Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

Abstract excerpt

BACKGROUND: The most common genetic changes identified in human NSCLC are Kras mutations (10-30 %) and p53 mutation or loss (50-70 %). Moreover, NSCLC with mutations in Kras and p53 poorly respond to current therapies, so we are trying to find a new target for the treatment strategies. METHODS: Flow cytometry, crystal violet staining and immunoblotting were used to assess cell cycle arrest, proliferation and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Hypoxia, and Metabolism
• Share to Erythrocyte Function and Pathophysiology
• Share to Glycosylation and Glycoproteins Research